Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | Prostate cancer updates from ASCO 2018

Neal Shore • 1 Jun 2018
ASCO 2018
Genitourinary Cancer Prostate Cancer Abiraterone Enzalutamide Olaparib Pembrolizumab Radium-223

Promising genitourinary cancer updates were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. Neal Shore, MD, of Carolina Urologic Research Center, Myrtle Beach, SC, gives his top picks for advanced prostate cancer here. For metastatic castration-resistant prostate cancer (mCRPC), Dr Shore highlights updates in: the combination of olaparib with abiraterone (NCT01972217); pembrolizumab plus enzalutamide (NCT02312557); different dosing regimens of radium-223 (NCT02023697); and radiolabelled PSMA ligands for theranostics (12615000912583).

More from Neal Shore

0:56
KEYNOTE-676 cohort A: pembrolizumab plus BCG in recurrent HR NMIBC
Neal Shore • 26 Jan 2024
0:51
OS sensitivity analysis of darolutamide, docetaxel and ADT in ARASENS
Neal Shore • 26 Jan 2024
0:44
PROpel: gene-by-gene efficacy of olaparib and abiraterone in mCRPC
Neal Shore • 26 Jan 2024
0:39
TALAPRO-2: rPFS and OS of talazoparib and enzalutamide in mCRPC
Neal Shore • 26 Jan 2024

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals